Each of OvaCure’s projects is conducted by world-leading experts within the fields of immunotherapy, oncology and gynaecology and is guided by OvaCure’s Scientific and Clinical Advisory Board.
Only ground-breaking projects are selected
In collaboration with the Anticancer Fund and the OvaCure Scientific and the Clinical Advisory Board, OvaCure has generated a project portfolio of two Danish and three international projects. Each project developed through OvaCure has maximum potential for the development of curative treatments for ovarian cancer patients.
OvaCure's first five projects are currently underway, with the flagship project, T-cell Infusion, being among the world's first trials to treat ovarian cancer patients with adoptive T-cell therapy (ACT). OvaCure’s 2nd project, T-cell Combination, will be conducted under the same clinical trial protocol and further the investigation by combining ACT with IFNα and chemotherapy. These two projects are the result of the OvaCure Innovation Summit in 2014, and have inspired the development of two additional international projects in Lausanne, which aim to develop novel personalised vaccination programs for ovarian cancer patients. OvaCure's Innovation Summits and Collaboration Labs in 2016 have also initiated, co-created and developed two additional projects, Genetic-Match and CAR T-cell Project, which are planned to start December 2016.